(AGENPARL) – gio 30 giugno 2022 Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update
Lund, Sweden June 30, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-June 2022 at 8:00 CET on July 19, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. [Link to presentation](https://publish.ne.cision.com/l/diaarrxlc/investors.hansabiopharma.com/English/events-and-presentations/presentations/default.aspx)
To participate in the telephone conference, please use the dial-in details provided below:
The webcast will be available on https://streams.eventcdn.net/hansa/q2-2022/
Participant access code: 729818
Updated Calendar and Events 2022
July 19, 2022 Half year 2022 report
Aug 9, 2022BTIG Biotechnology Conference 2022, New York
Aug 10, 2022Canaccord Annual Growth Conference, Boston
Aug 11-12, 2022Kempen US non-deal road show
Aug 18, 2022Penserpodden ”Focus on autoimmunity” (virtual)
Aug 31, 2022Redeye Late Stage Life Science conference, Stockholm
Sept 7, 2022Pareto annual Healthcare Conference 2022, Stockholm
Sept 7-8, 2022 Citi’s 17th Annual BioPharma Conference, Boston
Sept 12-14, 2022MorganStanley Global Healthcare Conference, New York
Sept 20, 2022Redeye Afterwork presentation, Gothenburg
Sept 21, 2022Redeye Lunch presentation, Stockholm
Sept 26, 2022Aktiespararna Aktiedagen, Lund
Oct 20, 2022Interim Report for January-September 2022
Nov 23, 2022Økonomisk Ugebrev Life Science Conference, Copenhagen
Nov 24, 2022Redeye Life Science Day, Stockholm
Dec 1, 2022Erik Penser Banks Temadag – Health Care, Stockholm
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Katja Margell
Head of Corporate Communications
Hansa Biopharma
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at [www.hansabiopharma.com](https://publish.ne.cision.com/l/diaarrxlc/hansabiopharma.com).
—————————————————————
This information was brought to you by Cision http://news.cision.com